Pathological Characteristics, Biochemical Recurrence and Functional Outcome in Radical Prostatectomy Patients on Statin Therapy

Abstract

Introduction: We assessed the pathological characteristics of the radical prostatectomy specimen, the rate of biochemical failure and the functional outcome after surgery, in terms of incontinence and erectile dysfunction rate, in patients on statin medication. Materials and Methods: A total of 588 patients with a mean age 65.2 years (SD = 5.7 years) participated in the study. All patients were contacted and interviewed. Results: Users who had been on statin medication for more than 2 years had lower levels of preoperative serum PSA (p = 0.034), a 2.76 times greater likelihood of being staged as pT3a to pT3b rather than pT2a to pT2c, and a 5.39 times greater likelihood of having a postoperative Gleason score equal to seven or more. Positive surgical margins and urinary incontinence were not significantly associated with statin use. The probability of erectile dysfunction was significantly greater for statin users. Conclusion: Statin medication was associated with a statistically significantly lower PSA value and an increased rate of high Gleason score and pathologic stage in patients receiving medication for more than 2 years. Statins were found to be an independent predictor of recurrence. Lastly, statin users were more likely to present with preoperative and postoperative erectile dysfunction.

The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis

“…A total of 3229 publications were identified during the initial search (see Additional file 1. ), and after employing exclusion criteria, a total of 22 studies were included for PCa recurrence analysis 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 ( Table 1 ), 8 trials were available for PCa-specific mortality 22 30 31 32 33 34 35 36 ( Table 2 ), and 13 for BCR-free survival analysis 8 9 11 14 17 20 25 29 36 37 38 39 40 ( Table 3 ). Among 22 studies included in meta-analysis for PCa recurrence, 14 included a population primarily treated with radical prostatectomy (RP).…”

A Review of Statin Use and Prostate Cancer

“…Patients in this trial were followed 588 patients (mean age of 65.2 years) for a median of 3.4 years [34].…”

Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes

“…[8][9][10][11][12][13][14][15][16] A recent meta-analysis showed that statins reduce the total incidence of PCa as well as the risk of clinically important advanced PCa. 17 Although several individual studies have indicated a beneficial effect of statins in reducing BCR risk and cancer-specific mortality after diagnosis, [18][19][20] meta-analyses have not revealed a consistently significant effect. 21 Meta-analyses have also failed to show a significant association between metformin use and PCa incidence.…”